Lifestyle intervention tied to weight loss, better DFS in breast cancer
A lifestyle intervention programme focusing on healthy habits was associated with weight loss and better disease-free survival (DFS) among early breast cancer survivors, according to the SUCCESS C* study presented at SABCS 2018.
Data from 2,292 women (median age 57 years, BMI of 24.0–40.0 kg/m2) with HER2-** early breast cancer who were previously treated with chemotherapy in SUCCESS C* were analysed in this study. The current study further randomizes the patients to receive either telephone-based lifestyle intervention programme (LI arm, n=1,146) or only general recommendations for a healthy lifestyle as control (non-LI arm, n=1,146). [SABCS 2018, abstract GS5-03]
The lifestyle intervention programme is a personalized approach, whereby patients received telephone calls advising them on how to improve diet, reduce fat intake, and increase physical activity for 2 years to achieve weight loss.
At 2 years of follow-up, patients who underwent lifestyle intervention programme lost an average of 1.0 kg of body weight, whereas those in the control group had a weight gain of 0.95 kg.
For both groups of patients, a significantly better DFS was observed in the 1,477 patients who completed the programme than those who did not (hazard ratio [HR], 0.35, 95 percent confidence interval [CI], 0.27–0.45; p<0.001).
In an explorative subgroup analysis of DFS among completers, DFS was significantly better among patients in the LI arm compared with the non-LI arm (HR, 0.51, 95 percent CI, 0.33–0.78; p=0.002 for multivariable adjusted cox regression and HR, 0.53, 95 percent CI, 0.35–0.82; p=0.004 for univariable analysis).
“[These explorative and non-planned interim analyses] suggests that the completion of systematic telephone-based lifestyle intervention program[me] does positively impact BMI and may improve outcome in overweight patients with early breast cancer,” said lead author Professor Wolfgang Janni from the Department of Obstetrics and Gynecology at the University of Ulm, Germany, who also added that caution is warranted in interpreting the results of this exploratory interim analysis, primarily due to a possible bias between completers and non-completers.
“[Furthermore,] lifestyle intervention might improve the prognosis of breast cancer patients if adherence is high,” Janni said. “This was highly feasible program[me] to design and implement, and further studies are warranted to confirm its effectiveness.”
*SUCCESS C: Docetaxel based anthracycline free adjuvant treatment evaluation, as well as life style intervention
** HER2-: Human epidermal growth factor receptor 2-negative